Oculis Holding AG (NASDAQ:OCS) Sees Significant Growth in Short Interest

Oculis Holding AG (NASDAQ:OCS) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 316,332 shares, an increase of 212.7% from the December 15th total of 101,167 shares. Currently, 0.6% of the shares of the stock are sold short. Based on an average trading volume of 114,783 shares, the days-to-cover ratio is currently 2.8 days. Based on an average trading volume of 114,783 shares, the days-to-cover ratio is currently 2.8 days. Currently, 0.6% of the shares of the stock are sold short.

Oculis Trading Down 0.6%

OCS stock traded down $0.14 during trading on Tuesday, hitting $23.01. The company had a trading volume of 91,213 shares, compared to its average volume of 202,555. The firm has a 50-day moving average price of $19.99 and a 200-day moving average price of $18.99. Oculis has a 12 month low of $14.00 and a 12 month high of $24.50. The company has a quick ratio of 4.47, a current ratio of 4.47 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -9.12 and a beta of 0.31.

Oculis (NASDAQ:OCS) last released its earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. The company had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.23 million. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%. As a group, analysts predict that Oculis will post -2.09 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on OCS. Chardan Capital reissued a “buy” rating and set a $51.00 price target on shares of Oculis in a report on Tuesday, November 11th. Wall Street Zen upgraded shares of Oculis from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. JPMorgan Chase & Co. began coverage on Oculis in a research report on Friday, December 19th. They set an “overweight” rating and a $38.00 price target on the stock. Bank of America cut their price objective on Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $36.00 price objective on shares of Oculis in a research note on Tuesday, November 11th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Oculis presently has an average rating of “Moderate Buy” and an average target price of $41.50.

Institutional Investors Weigh In On Oculis

Institutional investors have recently modified their holdings of the business. Aventura Private Wealth LLC acquired a new position in Oculis in the fourth quarter valued at approximately $80,000. Bosun Asset Management LLC bought a new stake in shares of Oculis during the 2nd quarter valued at $378,000. Marshall Wace LLP bought a new stake in shares of Oculis during the 2nd quarter valued at $393,000. Geode Capital Management LLC lifted its stake in shares of Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after purchasing an additional 6,384 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares during the last quarter. Institutional investors and hedge funds own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.